ALK-positive large B-cell lymphoma: A study of six cases from an oncopathology center in North India

ALK-positive large B-cell lymphoma (ALK+ LBCL) is a rare neoplasm with an aggressive course and poor therapeutic response to the standard R-CHOP regimen. Owing to its negativity for usual B- and T-cell markers and immunopositivity for epithelial markers, it can be easily misdiagnosed if it is not co...

Full description

Saved in:
Bibliographic Details
Main Authors: Ajita Verma, Zachariah Chowdhury, Anil Singh, Abhinav Kant, Anil Yadav, Shashikant C.U. Patne
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2025-01-01
Series:Indian Journal of Pathology and Microbiology
Subjects:
Online Access:https://journals.lww.com/10.4103/ijpm.ijpm_369_24
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849739271417626624
author Ajita Verma
Zachariah Chowdhury
Anil Singh
Abhinav Kant
Anil Yadav
Shashikant C.U. Patne
author_facet Ajita Verma
Zachariah Chowdhury
Anil Singh
Abhinav Kant
Anil Yadav
Shashikant C.U. Patne
author_sort Ajita Verma
collection DOAJ
description ALK-positive large B-cell lymphoma (ALK+ LBCL) is a rare neoplasm with an aggressive course and poor therapeutic response to the standard R-CHOP regimen. Owing to its negativity for usual B- and T-cell markers and immunopositivity for epithelial markers, it can be easily misdiagnosed if it is not contemplated. To study the clinicopathological parameters of cases of ALK+ LBCL diagnosed at our institution. A retrospective observational study of ALK+ LBCL was conducted at a tertiary cancer center of North India with cases diagnosed over a period of 3 years. Six cases of ALK+ LBCL were identified. The clinical findings at presentation included mean age of 38.8 years, male-to-female ratio of 5:1, extranodal presentation (1/6 cases), concurrent extranodal and nodal involvement (3/6), nodal presentation (2/6), high serum LDH (5/5), and bone marrow involvement (1/5). Histomorphology of diffuse (100%), alveolar/nested (16.6%), and sinusoidal pattern (1 case upon relapse) and immunoblastic and plasmablastic morphology (100%) and immunopositivity in all cases for ALK-1 protein (100%), CD138 (100%), MUM1 (100%), LCA (100%) along with negativity for EBER-ISH/EBV-LMP1 immunohistochemistry clinched the diagnosis. Fluorescence in situ hybridization analysis for ALK gene rearrangement was detected in 4/4 cases. Four patients received chemotherapy demonstrating relapse in 2 cases: residual disease and no response in one case each, along with death in 2 cases. A high degree of diagnostic suspicion is required for accurate recognition of ALK+ LBCL. Awareness of its histology, immunohistochemistry, and cytogenetics is pivotal for precise identification of this rare entity.
format Article
id doaj-art-9c4d227479124ad4bfe0b16b7717bb35
institution DOAJ
issn 0377-4929
0974-5130
language English
publishDate 2025-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Indian Journal of Pathology and Microbiology
spelling doaj-art-9c4d227479124ad4bfe0b16b7717bb352025-08-20T03:06:19ZengWolters Kluwer Medknow PublicationsIndian Journal of Pathology and Microbiology0377-49290974-51302025-01-0168114114610.4103/ijpm.ijpm_369_24ALK-positive large B-cell lymphoma: A study of six cases from an oncopathology center in North IndiaAjita VermaZachariah ChowdhuryAnil SinghAbhinav KantAnil YadavShashikant C.U. PatneALK-positive large B-cell lymphoma (ALK+ LBCL) is a rare neoplasm with an aggressive course and poor therapeutic response to the standard R-CHOP regimen. Owing to its negativity for usual B- and T-cell markers and immunopositivity for epithelial markers, it can be easily misdiagnosed if it is not contemplated. To study the clinicopathological parameters of cases of ALK+ LBCL diagnosed at our institution. A retrospective observational study of ALK+ LBCL was conducted at a tertiary cancer center of North India with cases diagnosed over a period of 3 years. Six cases of ALK+ LBCL were identified. The clinical findings at presentation included mean age of 38.8 years, male-to-female ratio of 5:1, extranodal presentation (1/6 cases), concurrent extranodal and nodal involvement (3/6), nodal presentation (2/6), high serum LDH (5/5), and bone marrow involvement (1/5). Histomorphology of diffuse (100%), alveolar/nested (16.6%), and sinusoidal pattern (1 case upon relapse) and immunoblastic and plasmablastic morphology (100%) and immunopositivity in all cases for ALK-1 protein (100%), CD138 (100%), MUM1 (100%), LCA (100%) along with negativity for EBER-ISH/EBV-LMP1 immunohistochemistry clinched the diagnosis. Fluorescence in situ hybridization analysis for ALK gene rearrangement was detected in 4/4 cases. Four patients received chemotherapy demonstrating relapse in 2 cases: residual disease and no response in one case each, along with death in 2 cases. A high degree of diagnostic suspicion is required for accurate recognition of ALK+ LBCL. Awareness of its histology, immunohistochemistry, and cytogenetics is pivotal for precise identification of this rare entity.https://journals.lww.com/10.4103/ijpm.ijpm_369_24alk d5f3alk-1cd-138crizotinibmum-1
spellingShingle Ajita Verma
Zachariah Chowdhury
Anil Singh
Abhinav Kant
Anil Yadav
Shashikant C.U. Patne
ALK-positive large B-cell lymphoma: A study of six cases from an oncopathology center in North India
Indian Journal of Pathology and Microbiology
alk d5f3
alk-1
cd-138
crizotinib
mum-1
title ALK-positive large B-cell lymphoma: A study of six cases from an oncopathology center in North India
title_full ALK-positive large B-cell lymphoma: A study of six cases from an oncopathology center in North India
title_fullStr ALK-positive large B-cell lymphoma: A study of six cases from an oncopathology center in North India
title_full_unstemmed ALK-positive large B-cell lymphoma: A study of six cases from an oncopathology center in North India
title_short ALK-positive large B-cell lymphoma: A study of six cases from an oncopathology center in North India
title_sort alk positive large b cell lymphoma a study of six cases from an oncopathology center in north india
topic alk d5f3
alk-1
cd-138
crizotinib
mum-1
url https://journals.lww.com/10.4103/ijpm.ijpm_369_24
work_keys_str_mv AT ajitaverma alkpositivelargebcelllymphomaastudyofsixcasesfromanoncopathologycenterinnorthindia
AT zachariahchowdhury alkpositivelargebcelllymphomaastudyofsixcasesfromanoncopathologycenterinnorthindia
AT anilsingh alkpositivelargebcelllymphomaastudyofsixcasesfromanoncopathologycenterinnorthindia
AT abhinavkant alkpositivelargebcelllymphomaastudyofsixcasesfromanoncopathologycenterinnorthindia
AT anilyadav alkpositivelargebcelllymphomaastudyofsixcasesfromanoncopathologycenterinnorthindia
AT shashikantcupatne alkpositivelargebcelllymphomaastudyofsixcasesfromanoncopathologycenterinnorthindia